fatty liver disease

Biotech

Madrigal's stock enters orbit after 2nd phase 3 NASH success

The tricky indication of nonalcoholic steatohepatitis has confounded many, but Madrigal Pharmaceuticals thinks it's finally onto a winner.
James Waldron Dec 19, 2022 10:05am

Nicotine-nomming gut bacteria could protect against NASH

Oct 21, 2022 1:05pm

Rivus raises $132M series B as metabolic pipeline heats up

Sep 22, 2022 10:41am

Pfizer gains fast-track tag for previously shelved NASH drug

May 26, 2022 9:05am

89bio gains a little more confidence in NASH treatment

Mar 25, 2022 11:00am

Rivus throws down liver fat data on quest to climb NASH mountain

Feb 9, 2022 9:27am